References
- Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–1608. S0140-6736(20) 31094-1.
- Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771–1778.
- Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79(8):999–1006.
- Whittaker E, Bamford A, and Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS- CoV-2. JAMA. 2020;324(3):259–269.
- Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. [cited 2021 Oct 10]. Available from: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisysteminflammatory-syndrome-temporally-associatedcovid-19
- World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. [cited 2021 Oct 19]. Available from:https://www.who.int/publications-detail/multisystem-inflammatorysyndrome-in-children-and-adolescents-withcovid-19
- Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. [cited 2021 Oct 10]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp
- Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome (MIS-C). [cited 2021 Oct 10]. Available from: https://www.cdc.gov/mis-c/cases/index.html
- Harwood R, Allin B, and Jones CE, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID- 19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2020;(2):133–141.
- Henderson LA, Canna SW, and Friedman KG, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS–CoV‐2 and hyperinflammation in pediatric COVID‐19: version 1. Arthritis Rheumatol. 2020;72(11):1791–1805.
- Cattalini M, Taddio A, and Bracaglia C, et al.; Rheumatology Study Group of the Italian Society of Pediatrics. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. Ital J Pediatr. 2021;47(1):24.
- Mastrolia MV, Maccora I, and Marrani E, et al. Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long. Clin Exp Rheumatol. 2021;39(3): 697–699 .
- Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6(4):232–241.
- Bukulmez H. Current understanding of Multisystem Inflammatory Syndrome (MIS-C) Following COVID-19 and its distinction from kawasaki disease. Curr Rheumatol Rep. 2021;23(8):58.
- Chou J, Platt CD, Habiballah S, et al. Taking on COVID-19 Together Study Investigators. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). JACI. 2021;148(3):732–738.e1.
- Mastrolia MV, Marrani E, and Calabri GB, et al. Fast recovery of cardiac function in PIMS-TS patients early using intravenous anti-IL-1 treatment. Crit Care. 2021;25(1):131.
- Belhadjer Z, Auriau J, Méot M, et al. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142(23):2282–2284.